Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma
Metrics: PDF 945 views | HTML 1001 views | ?
Hans Prenen1, Dominiek Smeets2,3, Massimiliano Mazzone4,5, Diether Lambrechts2,3, Xavier Sagaert6, Raf Sciot6, Maria Debiec-Rychter7
1Digestive Oncology, University Hospitals Leuven and Department of Oncology, KU Leuven, Leuven, Belgium
2Laboratory for Translational Genetics, Vesalius Research Center, Department of Oncology, KU Leuven, Leuven, Belgium
3Laboratory for Translational Genetics, Vesalius Research Center, VIB, Leuven, Belgium
4Laboratory of Molecular Oncology and Angiogenesis, Vesalius Research Center, Department of Oncology, KU Leuven, Leuven, Belgium
5Laboratory of Molecular Oncology and Angiogenesis, Vesalius Research Center, VIB, Leuven, Belgium
6Department of Pathology, KU Leuven and University Hospitals Leuven, Leuven, Belgium
7Department of Human Genetics, KU Leuven and University Hospitals Leuven, Leuven, Belgium
Hans Prenen, e-mail: email@example.com
Keywords: angiosarcoma, sunitinib, PLCG1 mutation, resistance, targeted therapy
Received: July 13, 2015 Accepted: September 26, 2015 Published: October 10, 2015
Hepatic angiosarcoma is a rare and aggressive vascular neoplasm. Pathogenic driver mutations are largely unknown. We present the case of a patient with recurrent hepatic angiosarcoma, who initially showed good response to sunitinib, followed by progression. Using comprehensive molecular techniques, we explored the potential mechanisms of resistance. By low-read-depth whole-genome sequencing, the comparison of copy number aberrations (CNAs) of the primary tumor to the skin metastatic lesion that developed after progression on sunitinib, revealed high-level amplification of the 4q11-q13.1 region (containing KIT, PDGFRA and VEGFR2 genes) that was sustained in both lesions. Whole exome sequencing on the germline, primary and metastatic tumor DNAs, resulted in 27 confirmed mutations, 19 of which (including TP53 mutation) presented in both primary and metastatic lesions. One mutation, ZNF331 frameshift deletion, was detected only in the primary tumor. In contrast, seven other mutations, including phospholipase C-gamma1 (PLCG1) R707Q mutation, were found only in the metastatic tumor, indicating selection of cells with the resistant genotype under sunitinib pressure. Our study supports the notion that PLCG1-R707Q mutation may confer VEGFR2-independent signaling and may thus cause resistance against VEGF(R)-directed therapies. This case illustrates also the advantages of using next-generation technologies in identifying individualized targeted therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.